Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Donald E. Bobo Jr., a Corporate Vice President at Edwards Lifesciences, exercised 5,000 stock options at a price of $45.2767 per share on November 13, 2024.
• On the same day, Mr. Bobo sold 5,000 shares of Edwards Lifesciences common stock at a weighted average price of $65.5686 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following these transactions, Mr. Bobo directly owns 46,935.7184 shares of common stock and indirectly owns 38,616.6145 shares through a 401(k) and 135,152 shares through a trust.
• Mr. Bobo also holds 35,500 employee stock options.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction, which is neither positive nor negative for the company's outlook. It is a neutral event.

Industry Context

This is a routine filing for insider transactions and is common for executives who have stock options and pre-arranged trading plans. It does not indicate any specific trend or change in the company's performance or outlook.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across publicly traded companies, particularly in the healthcare and medical device sectors.
• The use of 10b5-1 trading plans is a standard method for executives to avoid accusations of insider trading, and is widely adopted by companies such as Medtronic, Abbott, and Boston Scientific.
• The reported prices are within the normal trading range for Edwards Lifesciences stock, and the volume of shares traded is not unusual for an executive transaction.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not reflect a change in the company's fundamentals.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, executive compensation, share sale, Edwards Lifesciences, EW